Roger McIntyre

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Managing weight gain in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e23. 2009
  2. ncbi The role of atypical antipsychotics in bipolar depression and anxiety disorders
    Roger McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst Street, ECW 3D 003, Toronto, Ontario, M5T 2S9, Canada
    Bipolar Disord 5:20-35. 2003
  3. ncbi Comorbidity in bipolar disorder: a framework for rational treatment selection
    Roger S McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S9, Canada
    Hum Psychopharmacol 19:369-86. 2004
  4. ncbi Treating bipolar disorder. Evidence-based guidelines for family medicine
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 50:388-94. 2004
  5. ncbi The antidepressant effects of risperidone and olanzapine in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Clin Pharmacol 11:e218-26. 2004
  6. ncbi Bipolar disorder: a national health concern
    Roger S McIntyre
    University Health Network, Edith Cavell Wing 3D 003, 399 Bathurst St, M5T 2S8, Ontario, Canada
    CNS Spectr 9:6-15. 2004
  7. ncbi Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
    Roger S McIntyre
    University Health Network, and Department of Psychiatry, University of Toronto, Toronto, Ont
    CMAJ 172:57-9. 2005
  8. ncbi Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 66:28-36. 2005
  9. ncbi Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Ann Clin Psychiatry 17:83-93. 2005
  10. ncbi Open-label adjunctive topiramate in the treatment of unstable bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychoparmacology Unit, University Health Network, Toronto, Ontario
    Can J Psychiatry 50:415-22. 2005

Detail Information

Publications83

  1. ncbi Managing weight gain in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e23. 2009
    ....
  2. ncbi The role of atypical antipsychotics in bipolar depression and anxiety disorders
    Roger McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst Street, ECW 3D 003, Toronto, Ontario, M5T 2S9, Canada
    Bipolar Disord 5:20-35. 2003
    ..Thus, atypical antipsychotics represent an important therapeutic option for the treatment of bipolar disorder, providing improvements in manic, depressive, and anxiety symptoms...
  3. ncbi Comorbidity in bipolar disorder: a framework for rational treatment selection
    Roger S McIntyre
    Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S9, Canada
    Hum Psychopharmacol 19:369-86. 2004
    ..This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area...
  4. ncbi Treating bipolar disorder. Evidence-based guidelines for family medicine
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 50:388-94. 2004
    ..To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office...
  5. ncbi The antidepressant effects of risperidone and olanzapine in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Clin Pharmacol 11:e218-26. 2004
    ..To describe the antidepressant effectiveness of olanzapine and risperidone and compare their tolerability when employed adjunctively in bipolar I/II disorder...
  6. ncbi Bipolar disorder: a national health concern
    Roger S McIntyre
    University Health Network, Edith Cavell Wing 3D 003, 399 Bathurst St, M5T 2S8, Ontario, Canada
    CNS Spectr 9:6-15. 2004
    ....
  7. ncbi Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
    Roger S McIntyre
    University Health Network, and Department of Psychiatry, University of Toronto, Toronto, Ont
    CMAJ 172:57-9. 2005
  8. ncbi Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 66:28-36. 2005
    ..This article reviews relevant adverse events attributable to the use of atypical antipsychotic agents, with particular consideration of the bipolar disorder population...
  9. ncbi Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Ann Clin Psychiatry 17:83-93. 2005
    ..Preliminary investigations indicate that patients who suffer from BD with comorbid DM have a more severe course and outcome, lower quality of life, higher prevalence of medical comorbidity and higher cost of illness...
  10. ncbi Open-label adjunctive topiramate in the treatment of unstable bipolar disorder
    Roger S McIntyre
    Mood Disorders Psychoparmacology Unit, University Health Network, Toronto, Ontario
    Can J Psychiatry 50:415-22. 2005
    ..To assess open-label adjunctive topiramate in the treatment of outpatients with unstable bipolar disorder (BD)...
  11. ncbi Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
    ..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
  12. ncbi The human cost of not achieving full remission in depression
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario
    Can J Psychiatry 49:10S-16S. 2004
    ....
  13. ncbi Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia
    Roger S McIntyre
    Mood Disorders Psychopharmacology Clinic, Department of Psychiatry, University of Toronto, University Health Network, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T2S8
    Can J Psychiatry 48:689-94. 2003
    ..This investigation describes comparative NAP-induced weight gain in a prospective naturalistic cohort of persons with schizophrenia and related psychotic disorders...
  14. ncbi What to do if an initial antidepressant fails?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ont
    Can Fam Physician 49:449-57. 2003
    ..To provide family physicians with practical ways of managing depressed patients responding insufficiently to initial antidepressant treatment...
  15. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Bipolar Disord 7:5-69. 2005
    ..These guidelines also discuss issues related to bipolar disorder in women and those with comorbidity and include a section on safety and monitoring...
  16. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada
    Bipolar Disord 8:721-39. 2006
    ..The importance of comorbid psychiatric and medical conditions cannot be understated, and this update provides an expanded look at the prevalence, impact and management of comorbid conditions in patients with bipolar disorder...
  17. ncbi Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Ontario
    Can J Psychiatry 51:274-80. 2006
    ..We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables...
  18. ncbi Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Affect Disord 100:S5-14. 2007
    ..This post-hoc analysis aims to extend our understanding of quetiapine's antimanic efficacy by evaluating its therapeutic effect across the full spectrum of manic symptoms...
  19. ncbi Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited
    Roger S McIntyre
    Mood Disorders Program, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:15-20. 2002
    ..Most of their adverse effects can be avoided by slow titration toward the recommended doses. In contrast to carbamazepine and valproic acid, topiramate may be associated with weight loss...
  20. ncbi Asenapine versus olanzapine in acute mania: a double-blind extension study
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:815-26. 2009
    ..To assess the efficacy and tolerability of asenapine versus olanzapine in the extended treatment of bipolar mania...
  21. ncbi Acute treatment of patients with bipolar mixed episodes
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 69:e10. 2008
    ..As more medications become available in the treatment of bipolar disorder, algorithms can help clinicians make the appropriate treatment choices by offering recommendations for sequencing agents...
  22. ncbi Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, 399 Bathurst St, Toronto, Ontario, Canada M5T 2S8, Canada
    J Clin Psychiatry 70:5-11. 2009
    ....
  23. ncbi Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood and Anxiety Disorders Program, Center for Addiction and Mental Health, Clarke Site, Ontario, Canada
    Bipolar Disord 4:207-13. 2002
    ....
  24. ncbi When should you move beyond first-line therapy for depression?
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 71:16-20. 2010
    ..Taken together, practitioners are often faced with the critical question as to when to move beyond index therapy for treating depressive symptoms as part of MDD...
  25. ncbi Pharmacotherapy to sustain the fully remitted state
    Sidney Kennedy
    Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:269-80. 2002
    ..Medication should continue at the dose that was initially effective because using low-dose maintenance therapy appears to decrease the protective benefits...
  26. ncbi A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada
    Bipolar Disord 11:673-86. 2009
    ..Asenapine is approved for bipolar disorder and schizophrenia. This was a 3-week, randomized, double-blind, placebo-controlled trial of asenapine for treating acute bipolar mania...
  27. ncbi Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 68:1352-7. 2007
    ..This investigation was undertaken to explore the relationship between alcohol/illicit drug dependence and overweight/obesity in individuals with bipolar I disorder...
  28. ncbi Aripiprazole for the maintenance treatment of bipolar I disorder: A review
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Canada
    Clin Ther 32:S32-8. 2010
    ..Few pharmacologic agents have been approved by the US Food and Drug Administration for the maintenance treatment of bipolar disorder...
  29. ncbi Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial
    Roger S McIntyre
    University of Toronto, Toronto, ON, Canada M5T 2S8
    J Affect Disord 122:27-38. 2010
    ..This randomized, double-blind, placebo-controlled trial assessed the efficacy, safety, and tolerability of asenapine in bipolar I disorder...
  30. ncbi Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Clin Psychiatry 70:240-6. 2009
    ..To describe the rate and trajectory of change in psychiatric polypharmacy during the past decade in children and adolescents treated for major depressive disorder...
  31. ncbi Overview of managing medical comorbidities in patients with severe mental illness
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    J Clin Psychiatry 70:e17. 2009
    ..Coordinated somatic and psychiatric treatment, weight-neutral or weight-reducing pharmaceuticals, and behavioral weight management programs may help lessen the burden of CVD in the mental health population...
  32. ncbi Problem gambling in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Affect Disord 102:27-34. 2007
    ..This investigation was undertaken to explore the prevalence and associated features of problem gambling amongst individuals with bipolar I disorder...
  33. ncbi Predictors of self-reported antidepressant adherence
    Tara A Burra
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Behav Med 32:127-34. 2007
    ..Clinicians should be cognizant of this complexity and address not only issues related to medication efficacy and tolerability, but also social mediators and health beliefs when prescribing antidepressants...
  34. ncbi Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, ON, Canada
    Expert Opin Pharmacother 10:3061-75. 2009
    ..The data from the studies reviewed herein also indicate that quetiapine XR poses a low risk for extrapyramidal side effects in middle-aged and elderly individuals with major depressive disorder...
  35. ncbi Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, ON, Canada
    Dialogues Clin Neurosci 10:203-13. 2008
    ..Subphenotyping bipolar disorder as a function of comorbidity and temporality of onset may provide an opportunity for refining disease pathophysiological models and developing innovative disease-modifying therapies...
  36. ncbi Residual anxiety symptoms in depressed primary care patients
    Roger S McIntyre
    University of Toronto, Toronto, Ontario, Canada
    J Psychiatr Pract 13:125-8. 2007
    ..The goal of this study was to characterize the burden of anxiety among residual depressive symptoms in naturalistic primary care settings...
  37. ncbi Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets
    Nir Lipsman
    Division of Neurosurgery, University Health Network Department of Psychiatry, University of Toronto, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 12:691-701. 2010
    ..Herein, we provide the rationale for employing DBS as an alternative treatment avenue in individuals with bipolar depression...
  38. ncbi Bipolar disorder and suicide: research synthesis and clinical translation
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Psychiatry Rep 10:66-72. 2008
    ..A nascent database suggests that adjunctive psychosocial interventions may further reduce suicide risk in bipolar individuals...
  39. ncbi Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    Ann Clin Psychiatry 19:257-64. 2007
    ..A nascent explanatory theory regarding the pathophysiology of major depressive disorder posits that alterations in metabolic networks (e.g., insulin and glucocorticoid signaling) mediate allostasis...
  40. ncbi The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8
    Headache 46:973-82. 2006
    ..Opportunistic screening and surveillance for bipolar and comorbid migraine is warranted...
  41. ncbi Antipsychotic-induced weight gain: bipolar disorder and leptin
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 23:323-7. 2003
    ..05). The temporal association between weight increase and leptin changes does not support the notion that leptin is a primary promoter of antipsychotic-induced weight gain; however, a secondary perpetuating role cannot be ruled out...
  42. ncbi Valproate, bipolar disorder and polycystic ovarian syndrome
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Bipolar Disord 5:28-35. 2003
    ..Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS). This adverse event has not been systematically studied in bipolar disorder...
  43. ncbi Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Opin Pharmacother 6:707-13. 2005
    ..Pharmacoeconomic and cost-impact modelling analyses should be reformulated to consider duloxetine's symptom-alleviating effect on the somatic dimension of depressive illness...
  44. ncbi Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
    Arch Pediatr Adolesc Med 162:929-35. 2008
    ..To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics...
  45. ncbi The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Toronto, ON, Canada
    Expert Opin Drug Saf 5:523-37. 2006
    ..The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis...
  46. ncbi Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada
    Bipolar Disord 11:225-55. 2009
    ..Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder...
  47. ncbi Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Canada
    J Psychiatry Neurosci 30:178-86. 2005
    ..The available evidence suggests that a functional role for the cerebellum should be considered in future neuropsychiatric studies...
  48. ncbi Improving outcomes in depression: a focus on somatic symptoms
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    J Psychosom Res 60:279-82. 2006
    ..It is hypothesized that somatic symptom alleviation is a significant predictor of overall outcome in depressed primary care patients...
  49. ncbi Medical comorbidity in bipolar disorder: re-prioritizing unmet needs
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:406-16. 2007
    ..The aim of this review is to synthesize results from extant investigations which report on the co-occurrence of bipolar disorder and medical comorbidity...
  50. ncbi Anxiety disorders and bipolar disorder: a review
    Roger S McIntyre
    Department of Psychiatry and Pharmacology, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
    Bipolar Disord 8:665-76. 2006
    ..Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population...
  51. ncbi Assessing full remission
    Roger McIntyre
    Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:235-9. 2002
    ..A score of 3 or less on the Toronto HAM-D7 was found to correlate with the 17-item HAM-D definition of full remission (i.e., score of 7 or less)...
  52. ncbi Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Curr Diab Rep 9:51-9. 2009
    ..This article discusses the rate of co-occurrence and the points of pathophysiologic commonality between the metabolic syndrome and major depressive disorder...
  53. ncbi The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Saf 5:157-68. 2006
    ..To synthesise results from investigations reporting on the effect of antidepressants on glucose-insulin homeostasis...
  54. ncbi Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale
    Roger S McIntyre
    University of Toronto, Toronto, Ont
    CMAJ 173:1327-34. 2005
    ..We evaluated a 7-item abbreviated version (HAMD-7) of the 17-item Hamilton Depression Rating Scale (HAMD-17) in a randomized controlled clinical trial of patients with major depressive disorder being cared for in primary care settings...
  55. ncbi Reboxetine: a preliminary report on its use through the Special Access Program
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:418-22. 2002
    ..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...
  56. ncbi Teratogenesis associated with antibipolar agents
    Ha T T Nguyen
    Department of Psychiatry, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
    Adv Ther 26:281-94. 2009
    ..To review the teratogenic effects associated with the use of Food and Drug Administration-approved agents for bipolar disorder...
  57. ncbi Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Eval Clin Pract 16:744-55. 2010
    ....
  58. ncbi The relationship between testosterone and sexual function in depressed and healthy men
    Sakina J Rizvi
    University Health Network, Department of Psychiatry, Toronto, Canada
    J Sex Med 7:816-25. 2010
    ..The objective of this study is to evaluate the effects of depression and low testosterone across various domains of sexual function...
  59. ncbi Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Psychiatr Serv 57:1140-4. 2006
    ..This is the first cross-national population-based investigation exploring the prevalence and functional implications of comorbid general medical disorders in bipolar disorder...
  60. ncbi Aripiprazole: pharmacology and evidence in bipolar disorder
    Roger S McIntyre
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1001-9. 2007
    ..Aripiprazole constitutes an alternative mood-stabilizing pharmacologic avenue in bipolar disorder; its comparative efficacy in long-term recurrence prevention and bipolar depression is a future research vista...
  61. ncbi Bipolar disorder and ADHD: Clinical concerns
    Roger McIntyre
    University of Toronto, Canada
    CNS Spectr 14:8-9; discussion 13-4. 2009
    ..What has also been interesting along with these reports is that there has been emerging scientific studies implicating common brain regions and neural circuits subserving essential features of both conditions...
  62. ncbi Measurable outcomes in psychiatric disorders: remission as a marker of wellness
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Ther 28:1882-91. 2006
    ..Collectively, they are associated with significant morbidity, mortality, and economic cost. Wellness is the optimal outcome in the management of chronic medical and psychiatric disorders...
  63. ncbi The hepatic safety profile of duloxetine: a review
    Roger S McIntyre
    University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
    Expert Opin Drug Metab Toxicol 4:281-5. 2008
    ..Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert...
  64. ncbi Maintenance treatment in bipolar disorder: a focus on aripiprazole
    Roger S McIntyre
    University of Toronto, Department of Psychiatry, Department of Pharmacology, Toronto, ON, Canada
    Expert Rev Neurother 7:919-25. 2007
    ..This article provides a succinct review of treatments approved by the US FDA for maintenance in bipolar disorders, with a focus on the most recently approved atypical antipsychotic, aripiprazole...
  65. ncbi The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
    Joanna K Soczynska
    Institute of Medical Sciences, University of Toronto, Canada
    Neurotoxicology 30:497-521. 2009
    ..e. adalimumab, etanercept, and infliximab) on depressive symptoms and mental health-associated quality of life measures...
  66. ncbi Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street Toronto, ON, M5T 2S8, Canada
    Expert Opin Pharmacother 7:1305-21. 2006
    ..Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders...
  67. ncbi Relationship between regional brain metabolism, illness severity and age in depressed subjects
    Jakub Z Konarski
    Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Psychiatry Res 155:203-10. 2007
    ..The age-dependent changes documented herein may influence the distinct clinical presentation and treatment response described in older-age depression...
  68. ncbi Antidepressant augmentation with raloxifene
    Sophie Grigoriadis
    J Clin Psychopharmacol 25:96-8. 2005
  69. ncbi An approach to managing depression. Defining and measuring outcomes
    Atul Khullar
    Department of Psychiatry, University of Alberta, Edmonton
    Can Fam Physician 50:1374-80. 2004
    ..The 7-item Hamilton Depression Rating Scale can assist clinicians in determining when full remission has occurred...
  70. ncbi Antipsychotic drugs and diabetes
    Roger S McIntyre
    CMAJ 168:673. 2003
  71. ncbi Comorbidity in bipolar disorder: clinical and research opportunities
    Roger S McIntyre
    Bipolar Disord 8:645-7. 2006
  72. ncbi Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
    J Clin Psychiatry 69:514-9. 2008
    ....
  73. ncbi Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring
    Marie Josée Poulin
    Centre Hospitalier Affilie Universitaire De Quebec, Hopital de l Enfant Jesus, Quebec
    Can J Psychiatry 50:555-62. 2005
    ....
  74. ncbi Adverse events in children and adolescents treated with antipsychotic medications
    Jeanette M Jerrell
    Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, South Carolina 29203, USA
    Hum Psychopharmacol 23:283-90. 2008
    ..To report the odds of developing adverse events associated with antipsychotic treatment among children and adolescents...
  75. ncbi Bipolar depression: trial-based insights to guide patient care
    David E Kemp
    Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Dialogues Clin Neurosci 10:181-92. 2008
    ..A pragmatic clinical approach is presented for management of the depressed phase of bipolar disorder...
  76. ncbi Validity of conclusions about quetiapine
    Roger S McIntyre
    Am J Health Syst Pharm 65:114-5; author reply 115-6. 2008
  77. ncbi Bipolar depression: best practices for the outpatient
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    CNS Spectr 12:1-14. 2007
    ..Two case studies are presented to elucidate the best practices for the varying clinical states of bipolar disorder...
  78. ncbi Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program
    Linda S Kahn
    State University of New York at Buffalo, USA
    Int J Psychiatry Med 38:13-29. 2008
    ....
  79. ncbi Differentiating bipolar disorders from major depressive disorders: treatment implications
    David J Muzina
    Cleveland Clinic Neurological Institute, Psychiatry and Psychology, Cleveland, OH 44195, USA
    Ann Clin Psychiatry 19:305-12. 2007
    ..Bipolar disorder is a highly prevalent mood disorder, frequently misdiagnosed as unipolar major depressive disorder...
  80. ncbi Editorial: sharpening the focus in mood disorders: from disease models to individualized measurement-based care
    Roger S McIntyre
    Ann Clin Psychiatry 19:213-4. 2007
  81. ncbi Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo
    Paul E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Clin Psychiatry 68:1480-91. 2007
    ..Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks...
  82. ncbi Sex differences in antidepressant response in a Canadian primary-care sample
    Sophie Grigoriadis
    J Clin Psychopharmacol 27:95-8. 2007
  83. ncbi Varenicline and suicidality: a new era in medication safety surveillance
    Roger S McIntyre
    Expert Opin Drug Saf 7:511-4. 2008